Pharmacological Evaluation of Naproxen Metal Complexes on Antinociceptive, Anxiolytic, CNS Depressant, and Hypoglycemic Properties

Table 2

Central antinociceptive activity of naproxen and its metal chelates at different time intervals.

Group	Dose (mg/kg)	⁢Reaction time (sec)
		30 min; (% elongation)	60 min; (% elongation)	90 min; (% elongation)
Control	—	6.38 ± 0.34	5.86 ± 0.46	6.12 ± 0.23
Morphine	02	18.6 ± 0.59; (191.54)	15.86 ± 0.28; (170.65)	13.06 ± 0.72; (113.40)
Naproxen	25	9.97 ± 0.52; (56.27)	11.06 ± 0.45; (88.74)	10.46 ± 0.70; (70.92)
Naproxen	50	12.12 ± 0.62; (89.97)	11.94 ± 0.80; (103.75)	13.3 ± 0.42; (117.32)
Naproxen-copper complex	25	10.8 ± 0.33; (69.28)	10.8 ± 0.44; (84.30)	12.4 ± 0.34; (102.61)
Naproxen-copper complex	50	14.62 ± 0.42; (129.15)	14.8 ± 0.35; (152.56)	14.52 ± 0.49; (137.25)
Naproxen-cobalt complex	25	11.02 ± 0.48; (72.73)	11.32 ± 0.53; (93.17)	11.96 ± 0.50; (95.42)
Naproxen-cobalt complex	50	13.38 ± 0.34; (109.72)	15.3 ± 0.86; (161.09)	14.86 ± 0.44; (142.81)
Naproxen-iron complex	25	9.84 ± 0.79; (54.23)	10.78 ± 0.61; (83.96)	11.04 ± 0.52; (80.39)
Naproxen-iron complex	50	13.5 ± 0.84; (111.60)	13.64 ± 0.69; (132.76)	12.74 ± 0.87; (108.17)
Naproxen-silver complex	25	10.84 ± 0.55; (69.91)	11.06 ± 0.61; (88.74)	12.32 ± 0.45; (101.31)
Naproxen-silver complex	50	13.8 ± 0.58; (116.30)	14.18 ± 0.45; (141.98)	13.6 ± 0.42; (122.22)
Naproxen-zinc complex	25	12.48 ± 0.29; (95.61)	12.86 ± 0.51; (119.45)	12.18 ± 0.54; (99.02)
Naproxen-zinc complex	50	15.38 ± 0.45; (141.07)	15.44 ± 0.47; (163.48)	15.12 ± 0.31; (147.06)

Each value represents the mean ± SEM (). was considered significant compared with control.